跳至主要内容
临床试验/NCT07143266
NCT07143266招募中不适用

Multidisciplinary Approach to Elucidate the Pathophysiology of Sleep Disorders in Patients With Hypothalamic and Pituitary Damage

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60
试验地点
1
主要终点
Prevalence of sleep disorders in patients with hypothalamic and pituitary damage compared to healthy controls

研究概览

简要总结

Hypothalamus has a key role in multiple vital functions, including regulation of sleep-wake cycles. Oxytocin (OT), a neurohormone synthetized in the hypothalamus, has a wide range of physiological functions, including a putative role in improving sleep quality. Hypothalamic and pituitary damage (HPD) is associated with a clinically relevant OT deficient state and multiple and severe comorbidities including poor sleep quality, that have a well-known negative impact on general health and quality of life (QoL). Several factors may coexist in the pathophysiology of sleep disorders (SD) in HPD and SD might be a keystone in the persistence of some of the comorbidities observed in HPD. Therefore, appropriate identification and understanding of the mechanisms contributing to SD in HPD is mandatory to choose adequate preventive strategies and treatment. This project is aimed to (1) identify the prevalence of SD in HPD, (2) to determine OT role in sleep quality and (3) to identify potential mechanisms and mediators of sleep quality and their associations with clinical outcomes in patients with HPD with the ultimate goal of identifying preventive and therapeutic targets. We will use a controlled cross-sectional design of patients with HPD and sex-, BMI-, age- matched controls and an innovative cross-disciplinary approach bridging neuroendocrinology, psychology, neurophysiology, neuroimaging, nuclear medicine and neuroophthalmology disciplines to learn about the prevalence of SD in HPD and to disentangle the underpinning mechanisms behind SDs in HPD. The results of this project will be an extremely important step towards optimizing therapy for patients with HPD who have higher mortality and poor QoL despite appropriate hormone replacement therapy.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with hypothalamic-pituitary dysfunction (HPD) with at least one pituitary hormone deficiency and at least one clinical sign of hypothalamic damage (e.g., arginine-vasopressin deficiency (AVP-D) and/or severe obesity and/or hyperphagia; MRI suggestive of hypothalamic damage; traumatic brain injury; radiotherapy in the sellar region and/or brain tumors affecting the hypothalamus).
  • Healthy controls matched for BMI, age, and sex.

排除标准

  • Poor control of hormonal deficiencies in the previous 6 months.
  • Use of new psychoactive drugs in the last 3 months or occasional use.
  • Clinically significant liver, lung, kidney, and cardiovascular disease.
  • Any neurological condition affecting brain function (stroke, dementia, uncontrolled epilepsy with recent seizures).
  • Uncontrolled diabetes mellitus.
  • Active psychosis.
  • Ophthalmology: total blindness, Glaucoma, uveitis, visual acuity <0.6, or eye surgery in the previous 6 months.
  • Any acute illness that the investigator determines may interfere with study participation or safety.
  • Pregnancy or breastfeeding.
  • Patients who refuse or are unable to provide written informed consent.
  • In controls: presence of brain or pituitary tumor, radiation involving the hypothalamus or pituitary, and history of hypopituitarism.

结局指标

主要结局

Prevalence of sleep disorders in patients with hypothalamic and pituitary damage compared to healthy controls

时间窗: From enrollment to completion of the assessments at 3 months

Prevalence (%) of patients with sleep disorders (assessed by objective and subjective measures of sleep): * Impaired sleep quality assessed by Pittsburgh Sleep Quality Index (PSQI) and nocturnal polisomnography (PSG) * Daytime sleepiness assessed by Epworth Sleepiness Scale (ESS) * Obstructive Sleep Apnea (OSA) assessed by Berlin Questionnaire (BQ), Stop- BANG score risk and PSG * Insomnia assessed by Severity Index (ISI). * Daytime Sleepiness assessed by Multiple Sleep Latency Test (MSLT)

次要结局

  • Saliva oxytocin concentrations in patients compared to controls(From day 1 and day 2 of the objective sleep assessments (polisomnography and MSLT))
  • Urine 6-sulfametoxymelatonin concentrations in patients compared to controls(From day 1 and day 2 of the objective sleep assessments (polisomnography and MSLT))
  • Prevalence of Brain structural and perfusion abnormalities using Magnetic Resonance Imaging in patients compared to controls(From enrollment to completion of the assessment at 3 months)
  • Prevalence of glucose brain metabolism abnormalities using Fluorodeoxyglucose Positron Emission Tomography in patients and controls(From enrollment to completion of the assessment at 3 months)
  • Prevalence of patients with neuroophthalmological damage (in patients with HPD only) assessed by an expert neuro-ophthalmologist(Baseline)

研究者

发起方
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验